<DOC>
	<DOCNO>NCT00158886</DOCNO>
	<brief_summary>Patients rectal cancer candidate pre-operative radiation therapy may enrol Phase I , single center study . Patients full blood count , biochemistry , urinalysis , ECG safety evaluation . Sequential cohort three patient give increase dos oral topotecan fix dos concurrent radiation ( 45 Gy ) five week . The start dose oral topotecan 0.25 mg/m2 concomitantly administer radiation ( 45 Gy ) x 5 day every week unless radiation interrupt Holidays/Weekends toxicity require treatment delay occur . A total 25 dos plan .</brief_summary>
	<brief_title>Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients histologically confirm rectal cancer . Candidates preoperative radiotherapy . Primary tumor least 3cm clinical stage T2 , T3 , T4 N accord AstlerColler modification Dukes staging system . Eastern Cooperative Oncology Group ( ECOG ) performance status less 2 . Diagnosis rectal cancer 90 day start therapy . Evaluation H. Lee Moffitt Cancer Center . Recovery prior surgery life expectancy least 3 month . A primary tumor totally excised . Recurrent rectal cancer fail initial treatment . Exposure topotecan , infection , immunodeficiency , condition gastrointestinal ( GI ) tract would affect absorption , medication maintains motility/gastric empty . Any concomitant malignancy within last five year . Severe medical problem unrelated malignancy would limit compliance study . Patients child bear potential . Not practice adequate contraception . Patients pregnant lactate . Use investigational drug within 30 day 5 halflives first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>oral topotecan rectal cancer pelvic radiation</keyword>
</DOC>